DGHMC
TRIB

Dalton, Greiner, Hartman, Maher & Co’s Trinity Biotech TRIB Stock Holding History

Dalton, Greiner, Hartman, Maher & Co’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-899
Closed -$1.78M – 181
2016
Q3 		$1.78M Buy
899
+17
+2% +$31.7K 0.12% 126
2016
Q2 		$1.5M Sell
882
-531
-38% -$898K 0.09% 133
2016
Q1 		$2.47M Buy
1,413
+173
+14% +$275K 0.15% 104
2015
Q4 		$2.19M Buy
1,240
+263
+27% +$466K 0.13% 108
2015
Q3 		$1.68M Sell
977
-3
-0.3% -$7.24K 0.09% 119
2015
Q2 		$2.65M Buy
980
+13
+1% +$33.8K 0.14% 106
2015
Q1 		$2.79M Sell
967
-11
-1% -$30.5K 0.16% 103
2014
Q4 		$2.57M Buy
978
+194
+25% +$502K 0.14% 104
2014
Q3 		$2.15M Buy
784
+116
+17% +$377K 0.12% 109
2014
Q2 		$2.31M Sell
668
-3
-0.4% -$10.7K 0.12% 103
2014
Q1 		$2.44M Sell
671
-32
-5% -$126K 0.14% 102
2013
Q4 		$2.65M Sell
703
-195
-22% -$702K 0.15% 101
2013
Q3 		$2.93M Sell
898
-69
-7% -$202K 0.2% 103
2013
Q2 		$2.44M Buy
+967
New +$2.41M 0.19% 104

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
SCM
Stonehill Capital Management New York $350M AUM 73.6% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Dalton, Greiner, Hartman, Maher & Co's TRIB Position: Q4 2016 in Review

Dalton, Greiner, Hartman, Maher & Co sold out of Trinity Biotech (TRIB) in Q4 2016, closing a stake of 899 shares — an estimated $1.78M sold.

Dalton, Greiner, Hartman, Maher & Co first reported a position in TRIB in Q2 2013 and held it in 14 quarters. The position peaked at $2.93M in Q3 2013. 71 funds tracked by Wall St. Rank hold TRIB as of Q4 2016.

  • Dalton, Greiner, Hartman, Maher & Co reported no remaining Trinity Biotech position as of Q4 2016 after selling out during the quarter.
  • Dalton, Greiner, Hartman, Maher & Co sold 899 Trinity Biotech shares in Q4 2016, an estimated $1.78M.
  • Dalton, Greiner, Hartman, Maher & Co first reported a position in Trinity Biotech in Q2 2013 and held it in 14 quarters.
  • Dalton, Greiner, Hartman, Maher & Co's Trinity Biotech position peaked at $2.93M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2016.

Based on Dalton, Greiner, Hartman, Maher & Co's 13F filing for Q4 2016, filed 13 Jan 2017.